Kindred Healthcare acquires another hospital as it focuses on acute care

Louisville, Ky.-based Kindred Healthcare announced today its acquisition of a transitional care hospital in San Antonio, Texas, a move that supports its mission to add more long-term acute care facilities to its network.

Kindred, which posted a revenue of $7.2 billion in 2015, acquired the 44-bed facility, operated by Select Medical Holdings, a healthcare system in Mechanicsburg, Penn.

As part of a prior agreement announced June 1 in which Kindred acquired four leased hospitals from Select, Kindred sold them two in return. One of them was a 72-bed hospital in Atlanta.

“We have taken aggressive steps to reposition our long-term acute care portfolio (LTAC) in front of LTAC criteria,” said Benjamin A. Breier, Kindred’s president and CEO, in a statement. “We believe the five hospitals that we have acquired from Select will improve our ability to continue the care for our patients in several important markets.”

Kindred employs more than 100,000 people and offers services in 2,700 locations in 46 states.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.